Last reviewed · How we verify

TDF/3TC/EFV or DTG or NVP

MU-JHU CARE · FDA-approved active Small molecule

This is a combination antiretroviral regimen containing nucleoside reverse transcriptase inhibitors (TDF/3TC), a non-nucleoside reverse transcriptase inhibitor (EFV or NVP), or an integrase strand transfer inhibitor (DTG) that blocks HIV replication by inhibiting key viral enzymes.

This is a combination antiretroviral regimen containing nucleoside reverse transcriptase inhibitors (TDF/3TC), a non-nucleoside reverse transcriptase inhibitor (EFV or NVP), or an integrase strand transfer inhibitor (DTG) that blocks HIV replication by inhibiting key viral enzymes. Used for HIV-1 infection treatment and suppression.

At a glance

Generic nameTDF/3TC/EFV or DTG or NVP
SponsorMU-JHU CARE
Drug classAntiretroviral combination therapy (NRTI + NNRTI or INSTI)
TargetHIV reverse transcriptase, HIV integrase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

TDF (tenofovir) and 3TC (lamivudine) are nucleoside reverse transcriptase inhibitors that prevent HIV reverse transcriptase from converting viral RNA to DNA. EFV (efavirenz) and NVP (nevirapine) are non-nucleoside reverse transcriptase inhibitors that directly inhibit the same enzyme through a different mechanism. DTG (dolutegravir) is an integrase inhibitor that prevents viral DNA from integrating into the host genome. These agents are used in combination to suppress HIV replication and prevent resistance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: